Eli Lilly: Steep Pullback, Still Compelling Here
LLY's recent sell-off presents a buying opportunity for savvy investors, with strong growth potential in the GLP-1 market ahead. Explore more here.
Is Now a Good Time to Buy the Dip in Eli Lilly Stock?
From there, the case for or against investing in Lilly should become much clearer. Eli Lilly's earnings report
Is It Time to Sell Eli Lilly and Pfizer Stocks?
Arguably, no big pharma stocks have dominated the industry more over the last few years than Eli Lilly (NYSE: LLY) and Pfizer (NYSE: PFE). When the COVID-19 pandemic began in 2020, Pfizer quickly emerged as the leader in the race to develop a vaccine.
Eli Lilly Stock: Unexpected Developments (Rating Downgrade)
Eli Lilly faces challenges with slowing drug sales and a lawsuit against the HRSA. Learn why caution is advised for LLY stock despite its lower P/E ratio.
Eli Lilly Director Trades $233K In Company Stock
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
1 Stubborn Cloud and 2 Silver Linings for Eli Lilly Stock
Conditions are getting a bit more challenging for the drugmaker.
Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop
Eli Lilly, Novo Nordisk, and Amgen all look cheap. All of them could experience a massive boost to profits in the years to come.
Billionaire Israel Englander Increased His Stake In Eli Lilly During the Third Quarter: Should You?
After flying high during the first half of the year, pharmaceutical giant Eli Lilly (NYSE: LLY) has lost some momentum; the ...
Massive Insider Trade At Eli Lilly
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...
Healthy Returns: Eli Lilly's cholesterol pill impresses in mid-stage trial
The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...
Eli Lilly and Company: Lilly announces changes on board of directors
Eli Lilly and Company (NYSE: LLY) announced today that it has elected Jon Moeller as a new member of its board of directors ...
Yahoo Finance9d
Eli Lilly and Company (LLY)
Eli Lilly and Company (NYSE: LLY) announced today detailed results from the Phase 3 SURMOUNT-1 three-year study (176-week treatment period), the longest completed study to date of tirzepatide.
'Nuclear Option'?: Eli Lilly Taps Big Law Firms in Federal Drug Pricing Dispute
The Health Resources and Services Administration has “invoked the nuclear option of removal from not only the 340B program ...
Eli Lilly and Novo Want to Shake off Ozempic Copycats. Are They Ready to Meet Demand?
The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...
Eli Lilly and China-based biotech Laekna team on obesity drug
Earlier on Wednesday, Laekna, “a global biotech company focused on novel drug development for metabolic and cancer diseases,” accoding to its ...